Voyager Therapeutics (VYGR) Income Statement
Voyager Therapeutics Income Statement
Last quarter (Q2 2026), Voyager Therapeutics's total revenue was $3.17M, a decrease of 39.13% from the same quarter last year. In Q2, Voyager Therapeutics's net income was $-24.47M. See Voyager Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 40.37M | $ 80.00M | $ 250.01M | $ 40.91M | $ 37.41M | |
| $ -91.90M | $ 80.00M | $ 157.84M | $ -14.86M | $ -36.37M | |
| $ 39.94M | $ 163.29M | $ 35.82M | $ 35.98M | $ 37.25M | |
| Depreciation and Amortization | $ 4.06M | $ 4.73M | $ 4.44M | $ 6.19M | $ 5.17M |
| $ -115.52M | $ -59.61M | $ 138.18M | $ -39.65M | $ -66.03M | |
| $ -131.84M | $ -83.29M | $ 122.01M | $ -50.84M | $ -73.62M | |
| $ 12.27M | $ 18.95M | $ 11.72M | $ 4.45M | $ 2.42M | |
| $ -119.58M | $ -64.34M | $ 133.74M | $ -46.39M | $ -71.20M | |
| $ -119.72M | $ -65.00M | $ 132.33M | $ -46.41M | $ -71.20M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.04 | $ -1.13 | $ 3.08 | $ -1.21 | $ -1.75 |
| Diluted EPS | $ -2.04 | $ -1.13 | $ 2.97 | $ -1.21 | $ -1.75 |
| Weighted Average Shares Outstanding | 58.69M | 57.67M | 43.02M | 38.36M | 37.67M |
| Weighted Average Shares Outstanding (Diluted) | 58.69M | 57.67M | 44.57M | 38.36M | 37.67M |
Currency in USD
